German cannabis monograph methodology overview

Testing is performed in accordance with German pharmacopeial standards, which build upon European Pharmacopoeia (Ph. Eur.) principles while incorporating national regulatory expectations for medicinal cannabis. 

Identity testing

• Macroscopic and microscopic examination to confirm botanical identity and consistency
• Thin Layer Chromatography (TLC) for qualitative verification of cannabinoid profiles

Cannabinoid assays – DAB methodology

• Liquid Chromatography (LC)–based quantitative analysis of cannabinoids
• Precise determination of cannabinoid content to support labeling, batch release, and regulatory compliance

Safety and quality testing

• Heavy metals analysis (including arsenic, cadmium, lead, and mercury)
• Moisture content determination to support product stability and quality control
• Microbiology Testing (including total aerobic plate count, total yeast and moulds, bile tolerant gram-negative bacteria, E. coli, salmonella, staphylococcus aureus, pseudomonas aeruginosa in accordance to EP Pharmacopeia methods) 

All testing is conducted using validated methodologies appropriate for pharmaceutical‑grade medicinal cannabis products supplied to the German Market. 

Why German monograph compliance matters

• Market‑specific requirements: Germany applies some of the most stringent quality standards in Europe
• Medical supply chain readiness: Testing supports products intended for pharmacies and authorised distributors
• Pharmaceutical alignment: Ensures cannabis products meet expectations comparable to conventional medicinal products
• Regulatory confidence: Generates reliable data to support submissions, audits, and market authorisation

Meeting German monograph and regulatory expectations is critical for maintaining uninterrupted access to this high‑value medical cannabis market.